Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Stora Enso Q1 Profit Plunges - Quick Facts

Stora Enso Oyj (SEOAY.PK) reported first quarter net profit attributable to owners of 72.9 million euros or 0.09 euros per share, lower than 155.6 million euros or 0.20 euros per share a year ago.

Net profit, excluding non-recurring items, was 80.2 million euros, down from 175.3 million euros a year ago. Net profit per share, excluding non-recurring items, was 0.10 euros versus 0.22 euros last year.

Operational EBIT decreased year-over-year to 147 million euros, mainly due to lower prices in Printing and Reading and Biomaterials, and lower volumes in Renewable Packaging.

Sales declined to 2.67 billion euros from 2.73 billion euros in the prior-year quarter.

CEO Jouko Karvinen commented,

"Our first quarter earnings performance was overall in line with our guidance in February. However, the return on capital employed was below cost of capital, which shows the never-ending need to improve our cost position and operational performance. In addition to the expected price pressures and variable cost reductions only slowly improving our profit, we also had operational issues in several of our mills, for instance the Nordic mills of the Biomaterials Business Area. The good thing is that we can tackle these challenges ourselves, instead of just waiting for external conditions to improve.."

Moving ahead, in the second quarter of 2012, the company forecasts group sales to be slightly higher and operational EBIT approximately in the range of the first quarter of 2012 as there will be maintenance stoppages in several European mills and the benefits of improving variable costs are expected to become only slowly apparent in the results. The main maintenance impact is anticipated to be in the Biomaterials Business Area.

Register
To receive FREE breaking news email alerts for Stora Enso and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy. FCA US, until recently known as Chrysler, said Friday it is recalling 257,000 Dodge Ram pickups. The auto maker says the rear axle pinion nut on certain model year 2005 Dodge Ram 1500 trucks may loosen due to an undersized spline on the pinion gear. If the pinion nut loosens, the rear axle may... This medical device company has a very impressive track record of growing business over the past decade. increasing sales from $490.2 million in 2004 to $1.72 billion this year. The Silicone Hydrogel daily disposable lens portfolio constitutes a major avenue for growth.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.